论文部分内容阅读
目的检测特异性核基质结合蛋白(SATB1)和人表皮生长因子受体2(HER2)在乳腺癌中的表达,探讨其与乳腺癌分化程度的关系。方法应用免疫组织化学方法检测乳腺癌患者SATB1和HER2蛋白的表达,使用荧光原位杂交(FISH)方法检测HER2基因扩增状态,分析二者表达的相关性及与临床病理参数之间的关系。结果乳腺癌中存在SATB1与HER2的高表达,且二者呈正相关(r=0.425,P<0.05)。SATB1和HER2的表达与肿瘤组织分级有关,其共表达的肿瘤组织具有更高的组织学分级,与Ⅲ级乳腺癌相关(r=0.472,P<0.05)。结论SATB1可调节乳腺癌中HER2的表达,SATB1/HER2双阳性表达是乳腺癌低分化的一个标志。
Objective To detect the expression of specific nuclear stromal binding protein (SATB1) and human epidermal growth factor receptor 2 (HER2) in breast cancer and to explore its relationship with the degree of breast cancer differentiation. Methods The expression of SATB1 and HER2 protein in breast cancer patients was detected by immunohistochemistry. The amplification status of HER2 gene was detected by fluorescence in situ hybridization (FISH). The correlation between the expression of HER2 gene and the clinicopathological parameters was analyzed. Results There was a positive expression of SATB1 and HER2 in breast cancer (r = 0.425, P <0.05). The expression of SATB1 and HER2 correlated with tumor grade. The co-expressed tumor tissues had higher histological grade, which was associated with grade Ⅲ breast cancer (r = 0.472, P <0.05). Conclusions SATB1 regulates the expression of HER2 in breast cancer. Double positive SATB1 / HER2 expression is a sign of poor differentiation in breast cancer.